Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Giovanni Di Perri"'
Autor:
Riccardo Casciaro, Carmen Fava, Sabrina Audagnotto, Elena Salvador, Ilaria Motta, Alberto Gaviraghi, Andrea Calcagno, L. Marinaro, Giovanni Di Perri, Stefano Bonora, Valeria Ghisetti, Mattia Trunfio
Publikováno v:
Antiviral Therapy. 25:327-333
Background Antiviral and immune-modulating properties of low-molecular-weight heparin (LMWH) against Coronaviridae have been reported by in vitro studies, but no in vivo evidence is yet available. We sought to know whether the timing of prophylactic
Autor:
Giovanna Fatiguso, Antonio D'Avolio, Amedeo De Nicolò, Jessica Cusato, Fabio Favata, Giovanni Di Perri, Lucio Boglione, Giuseppe Cariti, Sarah Allegra
Publikováno v:
Antiviral Therapy. 23:373-377
Background Recently, due to its high effectiveness and tolerability, the treatment of chronic hepatitis B with entecavir became a standard practice. However, limited knowledge is currently available about its pharmacokinetic behaviour and intracellul
Autor:
Valeria Ghisetti, Sabrina Audagnotto, Andrea Calcagno, Anna Lucchini, P. Bigliano, C. Montrucchio, L. Marinaro, Chiara Alcantarini, Stefano Bonora, Giovanni Di Perri
Publikováno v:
Antiviral therapy. 23(5)
Background HIV late presenters are at high risk of cytomegalovirus (CMV) reactivation and end-organ disease. CMV viraemia has been associated with poor survival but the effect of anti-CMV treatment has not been studied in this setting. Methods HIV-po
Autor:
Guido Palamara, Alessandra Latini, Evangelo Boumis, Carlo Federico Perno, Chiara Tommasi, Federica Forbici, Claudia Alteri, Francesca Ceccherini-Silberstein, Rita Bellagamba, Caterina Gori, Maria Mercedes Santoro, Andrea Antinori, Pasquale Narciso, Daniele Armenia, Raffaella Libertone, Carmela Pinnetti, Vanni Borghi, Mario Santoro, Emanuele Nicastri, Cristina Mussini, Lavinia Fabeni, Adriana Ammassari, Valerio Tozzi, Andrea Calcagno, Valentina Svicher, Massimo Andreoni, Giovanni Di Perri, Philippe Flandre, A. R. Buonomini
Publikováno v:
Antiviral Therapy; Vol 18
Background We tested whether pre-HAART viraemia affects the achievement and maintenance of virological success in HIV-1-infected patients starting modern first-line therapies. Methods A total of 1,430 patients starting their first HAART (genotype-tai
Autor:
Davide Bitetto, Andrea Marengo, Alessia Ciancio, Mario Rizzetto, Giovanni Di Perri, Antonio D'Avolio, Carlo Fabris, Pierluigi Toniutto, Milena Marietti, Alfredo Marzano
Publikováno v:
Antiviral therapy. 18(1)
Background Limited data are available on entecavir in Caucasian patients with HBV cirrhosis or chronic hepatitis B who are treated in the clinical practice. The aim was to evaluate the efficacy of entecavir in an Italian cohort of unselected patients
Autor:
Isabella Abbate, Alessandra Amendola, Maria Rosaria Capobianchi, Pasquale Narciso, Leopoldo Paolo Pucillo, Anna Loredana Gallo, Magdalena Viscione, Giovanni Di Perri, Gabriella Rozera, Jelena Ivanovic, Chiara Tommasi, Emanuele Nicastri, Stefano Bonora, Rita Bellagamba, Massimo Tempestilli
Publikováno v:
Antiviral therapy. 16(6)
Background Raltegravir is the first approved antiretroviral able to prevent HIV genome integration into the host chromosomes. The aim of the study is to test if raltegravir plasma concentrations can be associated with proviral DNA decline during ralt
Autor:
Matthijs, van Luin, Wendy P, Bannister, Amanda, Mocroft, Peter, Reiss, Giovanni, Di Perri, Gilles, Peytavin, José, Molto, Anders, Karlson, Antonella, Castagna, Marek, Beniowski, Jens D, Lundgren, David M, Burger
Publikováno v:
Antiviral therapy. 14(1)
Co1nflicting data exist regarding the effect of efavirenz (EFV) plasma concentrations on central nervous system (CNS) toxicity. We aimed to determine whether patients with high EFV plasma concentrations have an increased likelihood of toxicity-driven